Vasculitis & polymyalgia rheumatica
Comparative Effectiveness of Rituximab‐ Versus Cyclophosphamide‐Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis for the Risk of Kidney Failure and Mortality
Authors' conclusion
Rituximab- and cyclophosphamide-based remission induction strategies for AAV are associated with similar risks of kidney failure and death.
Study context
- Population
- PR3-ANCA+ and MPO-ANCA+ AAV patients diagnosed 2002–2019, Mass General Brigham AAV Cohort (mean age 61 years; 58% female; 69% renal involvement)
- Participants
- 595 participants
- Exposure
- Rituximab-based vs cyclophosphamide-based remission induction
- Rituximabn = 352
- Cyclophosphamiden = 243reference
- Outcome
- Composite of:
- Kidney failure
- Death
- Follow-up
- 5 years
Methodological detailsmultivariable Cox proportional hazards models, propensity score-matched analyses
- Multivariable Cox proportional hazards models
- Propensity score-matched analyses
Main finding
As reported in the abstract
Kidney failure or death
Rituximab vs CyclophosphamideHazard ratio (95% CI)
Multivariable-adjusted
1.03(0.55–1.93)
Propensity score-matched
1.05(0.55–1.99)
Observational data: associations, not effects.
Further findings
Kidney failure or death at 1 and 2 years, and in subgroups by renal involvement and severity and major organ involvement
- Findings similar
Original publication
Comparative Effectiveness of Rituximab‐ Versus Cyclophosphamide‐Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis for the Risk of Kidney Failure and Mortality. Arthritis Rheumatol. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →